Implementation of post-marketing surveillance: MDR and guidelines

The post-marketing surveillance (PMS) is a theme that is becoming more and more important in the frame of medical device regulations, as recently shown by the significant increase of the requirements according to Regulation (EU) 2017/745 (MDR).
The PMS is, however, not an absolute novelty of this regulation as it already existed in Directive 93/42/EEC that set surveillance as an implicit obligation, so that manufacturers had a wider margin of freedom: for the purpose of complying with such obligation, they could move in a wider field complying with the bland boundaries imposed by the directive.
With the Regulation such field has narrowed and borders have become clearer: manufacturers must strictly observe them to be compliant with the provisions.
The implementation of the new requirements has raised some worries in the business operators, and in particular in manufacturers, also because at the date of application of the MDR, no guidance had been published explaining the method of implementation and fulfilment of the post-marketing surveillance system.
However, the release of ISO/TR 20416 in 2020 provided a valid support to a PMS goal-oriented planning for different types of medical devices and has highlighted the connections with ISO 13485 and ISO 14971, stressing how with the regulation the PMS becomes integral part of the quality system as well as activity subject to risk analysis.
Once the PMS goals have been defined, medical device manufacturers can select the data sources, the data collection methods, the data analysis and the appropriate evaluation methods, taking into account specific requirements provided in the MDR.
It is important to notice that the Regulation not only simply requires that manufacturers report serious incidents to the relative Competent Authorities, but also that they carry out a trend analysis and report such trends, if any. In fact, article 88 of the MDR established the obligation for manufacturers to report:
“any statistically significant increase in the frequency or severity of incidents that are not serious incidents or that are expected undesirable side effects that could have a significant impact on the benefit-risk analysis and which have led or may lead to risks to the health or safety of patients, users or other persons that are unacceptable when weighed against the intended benefits. The significant increase shall be established in comparison to the foreseeable frequency or severity of such incidents in respect of the device, or category or group of devices in question, during a specific period as specified in the technical documentation and product information.”
At European level, there are two guidance documents released in the frame of surveillance, namely MDCG 2020-7 and MDCG 2020-8. These are the template to draft respectively the plan and the report of the post-market clinical follow-up (PMCF).
As established in part B of Annex XIV of the MDR, PMCF is intended as a continuous process updating the clinical evaluation and it is treated in the manufacturer’s post-marketing surveillance plan. In the realization of the PMCF, “the manufacturer shall proactively collect and evaluate clinical data from the use in or on humans of a device which bears the CE marking and is placed on the market or put into service within its intended purpose as referred to in the relevant conformity assessment procedure, with the aim of confirming the safety and performance throughout the expected lifetime of the device, of ensuring the continued acceptability of identified risks and of detecting emerging risks on the basis of factual evidence.”
Two memorandum letters were issued nationally by the Ministry of Health, one dated 8 July 2021 and one dated 11 October 2022, providing operational indications on the methods and timelines for the reports of serious incident, incidents other that the serious ones, complaints, safety corrective actions, as well as reports of periodic summaries and trend reporting.
The memorandum letters give detailed indications to economic operators and users (health professionals, users and patients) in terms of what, when and how to report; these apply while waiting for EUDAMED to be fully functioning, ensuring more transparency and a prompt and rapid response to events in the device vigilance network.
Previous Post
Next Post